

**AMENDMENTS TO CLAIMS:**

Claims 1-26 cancelled.

27. (New) A method of prophylaxis against a myocardial infarction in a patient undergoing cardiopulmonary bypass surgery, said method comprising the steps of:

- a) administering an anti-inflammatory agent to said patient prior to or simultaneously with the start of said surgery, and
- b) administering additional anti-inflammatory agent subsequent to the start of said surgery.

28. (New) The method of claim 27 wherein said surgery is coronary artery bypass graft surgery or heart transplant surgery.

29. (New) The method of claim 27 wherein said anti-inflammatory agent is a complement inhibitor.

30. (New) The method of claim 29 wherein said complement inhibitor is selected from the group consisting of a) an antibody directed against complement component C1, C2, C3, C4, C5, C6, C7, C8 or C9, b) an antibody against Factor D, Factor B, Factor P, MBL, MASP-1, or MASP-2, and c) CR1, LEX-CR1, MCP, DAF,

CD59, Factor H, cobra venom factor, FUT-175, y bind protein, complestatin, or K76COOH.

31. (New) The method of claim 29 wherein the complement inhibitor is an antibody against C5 which prevents the conversion of C5 into C5a and C5b.

32. (New) The method of claim 31 wherein said antibody is h5G1.1-scFv.

33. (New) The method of claim 27 wherein step (a) comprises a bolus administration of said anti-inflammatory agent.

34. (New) The method of claim 27 wherein step (b) comprises an infusion administration of said anti-inflammatory agent.

35. (New) The method of claim 34 wherein said infusion continues for at least about 24 hours.

36. (New) A method of prophylaxis against a myocardial infarction in a patient undergoing cardiopulmonary bypass surgery, said method comprising the step of administering an anti-inflammatory agent to said patient prior to or simultaneously with the start of said surgery such that said anti-inflammatory agent remains effective in preventing myocardial infarction for at least 24 hours.

37. (New) The method of claim 36 wherein said surgery is coronary artery bypass graft (CABG) surgery or heart transplant surgery.

38. (New) The method of claim 36 wherein said anti-inflammatory agent is a complement inhibitor.

39. (New) The method of claim 38 wherein said complement inhibitor is selected from the group consisting of a) an antibody directed against complement component C1, C2, C3, C4, C5, C6, C7, C8 or C9, b) an antibody against Factor D, Factor B, Factor P, MBL, MASP-1, or MASP-2, and c) CR1, LEX-CR1, MCP, DAF, CD59, Factor H, cobra venom factor, FUT-175, y bind protein, complestatin, or K76COOH.

40. (New) The method of claim 38 wherein the complement inhibitor is an antibody against C5 which prevents the conversion of C5 into C5a and C5b.

41. (New) The method of claim 40 wherein said antibody is h5G1.1-scFv.